BIAFBioAffinity Technologies Inc
BIAF
BioAffinity Technologies Inc3,542
Mkt Cap
$4.77MVolume
45,611.0052W High
$46.5352W Low
$0.693PE Ratio
-0.05BIAF Fundamentals
Price
$1.06Prev Close
$1.04Open
$1.0250D MA
$1.18Beta
1.56Avg. Volume
64,488.25EPS (Annual)
-$22.37P/B
0.41Rev/Employee
$164,246.00$11.43
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath Lung Noninvasive Early Detection Lung Cancer Test
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical...
Business Wire·5d ago
New Case Study Highlights Ability of bioAffinity Technologies CyPath Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study in...
Business Wire·11d ago
Clinical Utility of bioAffinity Technologies CyPath Lung Test Demonstrated in Real-World Case Study
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a new clinical case study...
Business Wire·13d ago
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and...
Business Wire·21d ago
bioAffinity Technologies Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that its wholly owned laboratory...
Business Wire·2mo ago
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
Zacks·3mo ago
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported...
Business Wire·4mo ago
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath Lung, the Companys noninvasive test for lung cancer, today announced...
Business Wire·4mo ago
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage...
Business Wire·5mo ago
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage...
Business Wire·5mo ago
<
1
2
...
>